Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation
Danyang LiiD, Oliver PainiD, Chiara FabbriiD, Win Lee Edwin WongiD, Chris Wai Hang LoiD, Stephan RipkeiD, Annamaria CattaneoiD, Daniel SoueryiD, Mojca Zvezdana DernovšekiD, Neven HenigsbergiD, Joanna HauseriD, Glyn LewisiD, Ole Mors, Nader Perroud, Marcella RietscheliD, Rudolf UheriD, Wolfgang Maier, Bernhard T. Baune, Joanna M. BiernackaiD, Guido BondolfiiD, Katharina DomschkeiD, Masaki KatoiD, Yu‐Li LiuiD, Alessandro SerrettiiD, Shih‐Jen TsaiiD, , Cathryn M. LewisiD
Abstract
Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. The association of CYP2C19 and CYP2D6 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR=1.46, 95% CI [1.03, 2.06], p=0.033, heterogeneity I2=0%, subgroup difference p=0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19 and CYP2D6, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. CYP2D6 structural variants cannot be imputed from genotype data, limiting inference of pharmacogenetic effects. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 33
- FWCI
- 2.61
- Field percentile
- top 7%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies
Chiara Fabbri, Katherine E. Tansey, … Cathryn M. Lewis·European NeuropsychopharmacologyPeer-reviewed·Jun 28, 2018
- Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects
Chris Q. Eijsbouts, Yunxuan Jiang, … Rebekah Ryanne Wu·The Pharmacogenomics JournalPeer-reviewed·Aug 1, 2026
- New insights on the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation
Chiara Fabbri, Katherine E. Tansey, … Cathryn M. Lewis·The Pharmacogenomics JournalPeer-reviewed·Nov 21, 2017
- Genome-wide meta-analyses of non-response to antidepressants identify novel loci and potential drugs
Elise M. Koch, Tuuli Jürgenson, … Kevin Sean O’Connell·medRxiv·Jul 13, 2024
- Evaluating the Clinical Impact of CYP2C19 and CYP2D6 on Amitriptyline Outcomes in a Real-World Chronic Pain Cohort
Bade Uckac, Santiago Díaz‐Torres, … Giovanni Esteves Ferreira·medRxiv·Jun 5, 2026
- Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: A population-based cohort study
Dinesh Velayutham, Kholoud Bastaki, … Puthen Veettil Jithesh·Cambridge Prisms Precision MedicinePeer-reviewed·Jan 1, 2025